Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

Transition in the management of COVID-19

A review of the current approaches to managing COVID-19, including diagnostic, therapeutic, and preventive measures.

16 Oct 2022

Total body PET/CT scans can effectively visualize systemic joint involvement in patients with arthritis

Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of The Journal of Nuclear Medicine.

14 Oct 2022

Metabolite discovery offers a potential way to address metabolic conditions

"Metabolism" describes the body's chemical changes that create the necessary materials for growth and overall health. Metabolites are the substances made and used during these metabolic processes - or, as a new discovery out of Scripps Research and its drug development arm, Calibr, indicates, they could also be potent molecules for treating severe diseases.

13 Oct 2022

Potent antibiotic-loaded bone-cement could be used to treat bone infections

Each year, 700,000 people die due to antibiotic resistance. A growing global population unfortunately generates a growing resistance to established antibiotic treatments - a threat that has been met with insufficient funding and dwindling inspiration, as commercial incentives for developing new antibiotics have fallen.

13 Oct 2022

Motif-based SARS-CoV-2 protein-human protein interactions as potential antiviral target sites

Researchers performed a ProP-PD (proteomic peptide phage display) analysis to identify peptides from intrinsically disordered human (host) proteome regions that bind with SARS-CoV-2 genome-encoded folded protein domains (PDs).

13 Oct 2022

New partnership creates an automated anatomic pathology slide-scanning solution

Sakura Finetek, a global leader in histopathology products and Evident Scientific, a wholly owned subsidiary of Olympus Corporation, and a global leader in microscopy and imaging solutions, today announced a collaboration to offer a full workflow solution for anatomic pathology slide preparation and high-resolution digital scanning in the Americas.

From Evident Corporation - Life Sciences 13 Oct 2022

$2.5 million CDC contract to fund one of the largest SARS-CoV-2 surveillance programs in the U.S.

A team led by Scripps Research scientists has been awarded a contract by the U.S. Centers for Disease Control & Prevention (CDC) in support of one of the largest SARS-CoV-2 surveillance programs in the United States.

11 Oct 2022

Researchers explore drug-repurposing candidates acting against nucleotide-binding pockets of multiple SARS-CoV-2 proteins

In a new study, researchers pursued direct-acting severe acute respiratory syndrome coronavirus-2 drugs that compete for nucleotide-binding pockets (NBPs) of SARS-CoV-2 proteins.

11 Oct 2022

Viagra and Cialis may not be suitable candidates for treating dementia, NIH DREAM study shows

Results from the National Institutes of Health's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study show that sildenafil (Viagra) and tadalafil (Cialis) may not be suitable candidates for treating dementia.

4 Oct 2022

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

In a new study, researchers evaluated the anti-cancer therapeutic efficacy of two structurally-unrelated small molecules, PAV-617 and PAV-951.

4 Oct 2022

What are the genetic associations of stroke pathogenesis across ancestry groups?

In new research, researchers identified genetic associations of stroke pathogenesis.

4 Oct 2022

Optibrium strengthens global AI drug discovery software operations with three key appointments

Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today announced three key appointments.

From Optibrium Ltd. 3 Oct 2022

Universal vaccine advancement through AI and recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng and Dr. Lurong Pan about how AI computing can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

From Sino Biological Inc. 3 Oct 2022

New algorithm may help predict the risk of Alzheimer's dementia

When people participate in studies of aging, they often want to know what their individual risks of developing dementia from Alzheimer's disease are. Washington University researchers have developed an algorithm that can help provide them with information about what their risks may be.

30 Sep 2022

Changes in temperature may be behind the link between circadian disruption and cancer

Disruptions in circadian rhythm - the ways that our bodies change in response to the 24-hour light and dark cycle - have been linked to many different diseases, including cancer.

28 Sep 2022

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a "paradigm shift" in how pharmaceutical laboratories test and produce new protein-based drugs, such as therapeutic monoclonal antibodies being developed to treat a variety of diseases, from cancers to infectious diseases.

27 Sep 2022

Areas hospitable to Lassa virus spread may extend in the next several decades

In the study, which appeared on September 27 in Nature Communications, scientists analyzed decades of environmental data associated with Lassa virus outbreaks, revealing temperature, rainfall and the presence of pastureland areas as key factors contributing to viral transmission.

27 Sep 2022

Metal compounds could be the solution for drug-resistant fungal infections

University of Queensland researchers say metal compounds could be the answer to the growing problem of drug-resistant fungal infections.

26 Sep 2022

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

Drug Discovery News and Research

Further Reading

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Transition in the management of COVID-19

Total body PET/CT scans can effectively visualize systemic joint involvement in patients with arthritis

Metabolite discovery offers a potential way to address metabolic conditions

Potent antibiotic-loaded bone-cement could be used to treat bone infections

Motif-based SARS-CoV-2 protein-human protein interactions as potential antiviral target sites

New partnership creates an automated anatomic pathology slide-scanning solution

$2.5 million CDC contract to fund one of the largest SARS-CoV-2 surveillance programs in the U.S.

Researchers explore drug-repurposing candidates acting against nucleotide-binding pockets of multiple SARS-CoV-2 proteins

Viagra and Cialis may not be suitable candidates for treating dementia, NIH DREAM study shows

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

What are the genetic associations of stroke pathogenesis across ancestry groups?

Optibrium strengthens global AI drug discovery software operations with three key appointments

Universal vaccine advancement through AI and recombinant technology

New algorithm may help predict the risk of Alzheimer's dementia

Changes in temperature may be behind the link between circadian disruption and cancer

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

Areas hospitable to Lassa virus spread may extend in the next several decades

Metal compounds could be the solution for drug-resistant fungal infections

Designing a new treatment to treat migraine effectively

Building confidence in drug discovery through reliable safety assessment eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo